



AIFA Board approves reimbursement of two medicinal products

At its meetings on 4 and 30 June 2025, the AIFA Board of Directors approved the eligibility for NHS reimbursement of one new chemical entity and two extensions of therapeutic indications for a medicinal product already reimbursed for other indications.

The newly approved chemical entity is **Kapruvia** (difelikefalin), indicated for the treatment of pruritus in adults with chronic kidney disease undergoing dialysis. Kapruvia works by stimulating human kappa opioid receptors, which play a role in modulating the perception of itching.

The two extensions of therapeutic indications concern the antiviral **Prevymis** (letermovir), which helps prevent the development or reactivation of cytomegalovirus (CMV) disease in immunocompromised patients following a stem cell or kidney transplant.